Ann Optom Contact Lens.
2022 Sep;21(3):109-113. 10.52725/aocl.2022.21.3.109.
The Matrix Metalloproteinase-9 Point-of-Care Test for Dry Eye Disease
- Affiliations
-
- 1Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea
- KMID: 2536978
- DOI: http://doi.org/10.52725/aocl.2022.21.3.109
Abstract
- Dry eye disease (DED) is a condition of the ocular surface characterized by tear film abnormalities and ocular symptoms; ocular surface inflammation is the principal pathogenesis. Recently, a matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay (InflammaDry) has become widely used as an ancillary diagnostic tool in routine clinical settings. This paper reviews the role of MMP-9 in DED, the relationships of MMP-9-positivity on the InflammaDry test with the symptoms and signs of DED, and specific considerations when performing the test.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Correlation between Tear Matrix Metalloproteinase-9 Concentration and Clinical Findings in Dry Eye Disease
- The Correlation between MMP-9 Point-of-Care Assay and Clinical Symptoms and Signs of Dry Eye Disease
- Comparative Evaluation of Matrix Metalloproteinase-9 Immunoassay and Tear Osmolarity Measurement for Diagnosing Severity of Dry Eye Disease
- Comparison of the Effects of 0.05% and 0.1% Cyclosporine for Dry Eye Syndrome Patients after Cataract Surgery
- Correlation Analysis between Ocular Surface Parameters with Subjective Symptom Severity in Dry Eye Disease
